Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

In the era of precision medicine, it is crucial to identify molecular alterations that will guide
the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) …

The incidence of melanoma, among the most lethal cancers, is widespread and increasing.
Metastatic melanoma has a poor prognosis, representing about 90% of skin cancer …

Melanoma heterogeneity is a hurdle in metastatic disease management. Although the
advent of targeted therapy has significantly improved patient outcomes, the occurrence of …

Detection of melanoma-associated mutations using circulating tumor DNA (ctDNA) from
plasma is a potential alternative to using genomic DNA from invasive tissue biopsies. In this …

Analysis of circulating tumor DNA (ctDNA) is a potential minimally invasive molecular tool to
guide treatment decision-making and disease monitoring. A suitable diagnostic-grade …

Simple Summary Malignant melanoma is the most lethal form of skin cancer. While new
therapeutic approaches have improved survival in patients with metastatic melanoma …

Despite remarkable progress in melanoma therapy, the exceptional heterogeneity of the
disease has prevented the development of reliable companion biomarkers for the prediction …

Circulating tumor DNA (ctDNA) is the cornerstone of liquid biopsy diagnostics, revealing
clinically relevant genomic aberrations from blood of cancer patients. Genomic analysis of …

Breast cancer is a highly heterogeneous and dynamic disease, exhibiting unique somatic
alterations that lead to disease recurrence and resistance. Tumor biopsy and conventional …